34 related articles for article (PubMed ID: 17728699)
1. G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders.
Wong TS; Li G; Li S; Gao W; Chen G; Gan S; Zhang M; Li H; Wu S; Du Y
Signal Transduct Target Ther; 2023 May; 8(1):177. PubMed ID: 37137892
[TBL] [Abstract][Full Text] [Related]
2. Preparation of 3-hydroxyquinolines from direct oxidation of dihydroquinolinium salts.
Ramanathan M; Wan J; Liu ST
RSC Adv; 2018 Nov; 8(67):38166-38174. PubMed ID: 35559109
[TBL] [Abstract][Full Text] [Related]
3. Neurokinin receptors and their implications in various autoimmune diseases.
Mishra A; Lal G
Curr Res Immunol; 2021; 2():66-78. PubMed ID: 35492389
[TBL] [Abstract][Full Text] [Related]
4. Harnessing the Anti-Nociceptive Potential of NK2 and NK3 Ligands in the Design of New Multifunctional μ/δ-Opioid Agonist-Neurokinin Antagonist Peptidomimetics.
Gadais C; Piekielna-Ciesielska J; De Neve J; Martin C; Janecka A; Ballet S
Molecules; 2021 Sep; 26(17):. PubMed ID: 34500841
[TBL] [Abstract][Full Text] [Related]
5. Crystal structure of the human NK
Yin J; Chapman K; Clark LD; Shao Z; Borek D; Xu Q; Wang J; Rosenbaum DM
Proc Natl Acad Sci U S A; 2018 Dec; 115(52):13264-13269. PubMed ID: 30538204
[TBL] [Abstract][Full Text] [Related]
6. Neurokinin-3 Receptor Binding in Guinea Pig, Monkey, and Human Brain: In Vitro and in Vivo Imaging Using the Novel Radioligand, [18F]Lu AF10628.
Varnäs K; Finnema SJ; Stepanov V; Takano A; Tóth M; Svedberg M; Møller Nielsen S; Khanzhin NA; Juhl K; Bang-Andersen B; Halldin C; Farde L
Int J Neuropsychopharmacol; 2016 Aug; 19(8):. PubMed ID: 26993630
[TBL] [Abstract][Full Text] [Related]
7. Characterization of RO4583298 as a novel potent, dual antagonist with in vivo activity at tachykinin NK₁ and NK₃ receptors.
Malherbe P; Knoflach F; Hernandez MC; Hoffmann T; Schnider P; Porter RH; Wettstein JG; Ballard TM; Spooren W; Steward L
Br J Pharmacol; 2011 Feb; 162(4):929-46. PubMed ID: 21039418
[TBL] [Abstract][Full Text] [Related]
8. The mammalian tachykinin ligand-receptor system: an emerging target for central neurological disorders.
Pantaleo N; Chadwick W; Park SS; Wang L; Zhou Y; Martin B; Maudsley S
CNS Neurol Disord Drug Targets; 2010 Nov; 9(5):627-35. PubMed ID: 20632965
[TBL] [Abstract][Full Text] [Related]
9. Neurokinin NK1 and NK3 receptors as targets for drugs to treat gastrointestinal motility disorders and pain.
Sanger GJ
Br J Pharmacol; 2004 Apr; 141(8):1303-12. PubMed ID: 15023866
[TBL] [Abstract][Full Text] [Related]
10. Neurokinin 3 (NK3) receptor modulators for the treatment of psychiatric disorders.
Smith PW; Dawson LA
Recent Pat CNS Drug Discov; 2008 Jan; 3(1):1-15. PubMed ID: 18221236
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo characterization of the non-peptide NK3 receptor antagonist SB-223412 (talnetant): potential therapeutic utility in the treatment of schizophrenia.
Dawson LA; Cato KJ; Scott C; Watson JM; Wood MD; Foxton R; de la Flor R; Jones GA; Kew JN; Cluderay JE; Southam E; Murkitt GS; Gartlon J; Pemberton DJ; Jones DN; Davies CH; Hagan J
Neuropsychopharmacology; 2008 Jun; 33(7):1642-52. PubMed ID: 17728699
[TBL] [Abstract][Full Text] [Related]
12. Augmentation of antipsychotic-induced neurochemical changes by the NK3 receptor antagonist talnetant (SB-223412).
de la Flor R; Dawson LA
Neuropharmacology; 2009 Feb; 56(2):342-9. PubMed ID: 18822303
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics.
Dawson LA; Langmead CJ; Dada A; Watson JM; Wu Z; de la Flor R; Jones GA; Cluderay JE; Southam E; Murkitt GS; Hill MD; Jones DN; Davies CH; Hagan JJ; Smith PW
Eur J Pharmacol; 2010 Feb; 627(1-3):106-14. PubMed ID: 19879867
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo characterization of NK3 receptors in the rabbit eye by use of selective non-peptide NK3 receptor antagonists.
Medhurst AD; Hay DW; Parsons AA; Martin LD; Griswold DE
Br J Pharmacol; 1997 Oct; 122(3):469-76. PubMed ID: 9351503
[TBL] [Abstract][Full Text] [Related]
15. Characterization of receptors mediating contraction induced by tachykinins in the guinea-pig isolated common bile duct.
Patacchini R; Barthó L; Maggi CA
Br J Pharmacol; 1997 Dec; 122(8):1633-8. PubMed ID: 9422808
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
